Axsome Therapeutics, Inc. (LON:0HKF)
182.61
-3.18 (-1.71%)
Feb 12, 2026, 4:58 PM GMT
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $170.99M USD in the quarter ending September 30, 2025, with 63.22% growth. This brings the company's revenue in the last twelve months to $561.26M, up 65.83% year-over-year. In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth.
Revenue (ttm)
$561.26M
Revenue Growth
+65.83%
P/S Ratio
16.48
Revenue / Employee
$687.82K
Employees
816
Market Cap
6.88B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
| Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
| Dec 31, 2022 | 50.04M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| CVS Group | 673.20M |
| Genus | 672.80M |
Axsome Therapeutics News
- 15 days ago - AXSM: Leerink Partners Raises Price Target to $205, Maintains Outperform Rating | AXSM Stock News - GuruFocus
- 16 days ago - Noteworthy Tuesday Option Activity: TSLA, CVLT, AXSM - Nasdaq
- 16 days ago - Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 - GlobeNewsWire
- 19 days ago - Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline - Seeking Alpha
- 21 days ago - FRANKLIN STREET ADVISORS INC /NC Buys 10,000 Shares of Axsome Therapeutics Inc (AXSM) - GuruFocus
- 22 days ago - AXSM: RBC Capital Raises Price Target to $219 with Outperform Rating | AXSM Stock News - GuruFocus
- 23 days ago - HC Wainwright & Co. Raises Price Target for AXSM to $260 | AXSM Stock News - GuruFocus
- 27 days ago - Piper Sandler Raises Axsome Therapeutics (AXSM) Price Target to $223 | AXSM Stock News - GuruFocus